Randomized Trial of Rosuvastatin for Acutely Injured Lungs From Sepsis

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rosuvastatin (Primary)
Indications Adult respiratory distress syndrome; Systemic inflammatory response syndrome
Focus Therapeutic Use
Acronyms SAILS

Most Recent Events

10 Jun 2021 Results (n=568) of secondary analysis of SAILS-ALTOS trial evaluating if subphenotype status was associated with differences in physical, mental health and cognitive outcomes, based on a prior prospective evaluation of SAILS patients over 6-month and 12-month follow-up published in the Thorax
20 May 2020 Results of secondary analysis presented at the 116th International Conference of the American Thoracic Society
17 Aug 2015 New trial record

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight